FLORHAM PARK, N.J., Oct. 18, 2022 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing…
Phase 1 Study Will Include Biomarker Selected Patients with Advanced Solid TumorsWILMINGTON, Del., Oct. 18, 2022 (GLOBE NEWSWIRE) -- Prelude…
TOWER ONE CONSTRUCTION UPDATE FOR THE MONTH OF SEPTEMBER 2022VANCOUVER, BC, CANADA, Oct. 18, 2022 (GLOBE NEWSWIRE) -- TOWER ONE…
CHICAGO and FORT WORTH, Texas, Oct. 18, 2022 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc., a Chicago-based clinical-stage biopharmaceutical company advancing…
Surgeons in 21 Countries Can Now Take Advantage of FlareHawk’s Minimal Insertion Profile, Multiplanar and Endplate-Conforming Expansion, and Maximum Graft…
Aligos’ pan-Coronavirus inhibitor, ALG-097558, is on track to begin first clinical studies in 1H 2023SOUTH SAN FRANCISCO, Calif., Oct. 18,…
Avicenna Academy Avicenna AcademyThe education portal provides modules, case studies and other resources related to medical cannabis for Health Care…
PHILADELPHIA, Oct. 18, 2022 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (Nasdaq: ANPC) (“AnPac Bio” or the “Company”), a…
Clinical collaboration with AstraZeneca announced for the evaluation of osimertinib in combination with IK-930 for patients with EGFR-mutant lung cancers…
– LX1004 is an adeno-associated virus (AAV) based gene therapy for the treatment of CLN2 Batten disease – – In…